Skip to main content
Figure 2 | Molecular Medicine

Figure 2

From: Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study

Figure 2

ARA 290 administration is associated with a time-dependent improvement of the SFNSL score. Reduction in SFNSL score from baseline (improvement) in the ARA 290 group occurs within the first week and continues for the whole duration of the dosing period. In contrast, a small, nonsignificant change in placebo patients appeared to reach a plateau. (Curves [mean ± SEM] are significantly different at the p < 0.05 level based on repeated-measures ANOVA).

Back to article page

Molecular Medicine

ISSN: 1528-3658